Shots:
- The P-III (GLORY-2) trial assessed mazdutide (9mg) plus lifestyle intervention vs PBO in 462 Chinese adults with obesity (BMI ≥30kg/m²), incl. 16% with T2D, with an NDA submission to the NMPA planned in the near term
- Trial met its 1EP, showing continuous weight loss with no plateau through Wk. 60, with pts achieving a mean weight reduction of 18.55% vs 3.02% & 44% vs 2.6% reaching ≥20% loss; in key 2EP, weight loss was 20.08% vs 2.81% in non-T2D pts, with 48.7% vs 3.1% reaching ≥20% weight loss
- Trial met all key 2EPs incl. body weight, waist circumference, BP, triglycerides, non-HDL-C, LDL-C, & serum uric acid levels, & in pts without T2D with baseline liver fat ≥10%, mazdutide reduced liver fat by 71.9% vs a 5.1% increase with PBO
Ref: Innovent Biologics | Image: Innovent Biologics | Press Release
Related News:- Innovent Reports the US FDA’s IND Clearance of IBI3032 for Cardiometabolic Disorders
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
